Cas no 56238-63-2 (Cefuroxime sodium)

Cefuroxime sodium is a second-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is the sodium salt of cefuroxime, enhancing solubility for parenteral administration. The compound exhibits stability against many β-lactamases, making it effective against resistant strains. Its key advantages include a well-established pharmacokinetic profile, with good tissue penetration and a favorable safety margin. Cefuroxime sodium is commonly used in treating respiratory, urinary, and soft tissue infections, as well as surgical prophylaxis. Its twice-daily dosing regimen improves patient compliance. The product is supplied as a sterile powder for reconstitution, ensuring stability and ease of use in clinical settings.

Cefuroxime sodium structure

Product Name:Cefuroxime sodium

CAS No:56238-63-2

MF:C₁₆H₁₅N₄NaO₈S

MW:446.367073297501

MDL:MFCD09878727

CID:56916

PubChem ID:24892692

Update Time:2026-04-13

Cefuroxime sodium Chemical and Physical Properties

Names and Identifiers

- Biociclin
- CEFUROXIME NA
- CEFUROXIME SODIUM
- CEFUROXIME SODIUM SALT
- sodium [6r-[6a,7b(z)]]-3-[[(aminocarbonyl)oxy]methyl]-7-[2-furyl(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- 7-beta(z)))-6-alph
- ethyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-,monosodiumsalt,(6r-(
- sodiumcefuroxime
- zinacef
- sodium [6R-[6alpha,7beta(Z)]]-3-[[(aminocarbonyl)oxy]methyl]-7-[2-furyl(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- Cefuroxime Sodium(sterile)
- Cefroxine
- (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-furanyl(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid Sodium Salt
- Anaptivan
- Biofurex
- Cefurin
- Duxima
- Novocef
- Zinace
- CEFUROXIME
- Sodium;(6S,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-th
- Cefuroxima Richet
- MLS001332626
- CEFUROXIME SODIUM [ORANGE BOOK]
- Froxal
- Colifossim
- CEFUROXIME SODIUM IN PLASTIC CONTAINER
- R8A7M9MY61
- Monosodium (6R,7R)-3-carbamoyloxymethyl-7-((Z)-2-furan-2-yl-2-(methoxyimino)acetylamino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
- CEFUROXIME SODIUM [EP MONOGRAPH]
- 56238-63-2
- 5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 3-(((AMINOCARBONYL)OXY)METHYL)-7-((2-FURANYL(METHOXYIMINO)ACETYL)AMINO)-8-OXO-, MONOSODIUM SALT (6R-(6.ALPHA.,7.BETA.(Z)))-
- 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, Monosodium Salt(6R-(6alpha,7beta(Z)))-
- UNII-R8A7M9MY61
- Cefuroxim Lilly
- Cefumax
- Cefuroxime for Injection and Dextrose for Injection in Duplex Container
- NSC 758166
- CXM
- MLS000069576
- Cefuroxime sodium 100 microg/mL in Acetonitrile/Water
- Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
- HMS2097O21
- Cefuroxima Fabra
- Cefuroxim Genericsn
- Cefuroxime (sodium)
- DTXSID201015616
- Lifurox
- 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, monosodium salt (6R-(6alpha,7beta(Z)))-
- Froxal [inj.]
- Cetroxil [inj.]
- Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester)
- Cefuroxim Norcox (inj.)
- Cefuroxime sodium [USP:BAN:JAN]
- Kefurox
- Cetroxil
- Zinacef (TN)
- Cefuroxime and Dextrose
- DTXCID301473853
- EINECS 260-073-1
- Sharox (inj.)
- Furoxil
- CHEMBL2146124
- Zinnat [inj.]
- Cefurex
- Cefuroxim curasan
- Curoxima
- CEFUROXIME SODIUM (MART.)
- HY-B1256
- CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER
- CEFUROXIME SODIUM (EP MONOGRAPH)
- CEFUROXIME SODIUM [EP IMPURITY]
- Cefuroxime sodium, United States Pharmacopeia (USP) Reference Standard
- AKOS015961772
- sodium (6R,7R)-3-(carbamoyloxymethyl)-7-((E)-2-(furan-2-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- CCG-220720
- ZINACEF IN PLASTIC CONTAINER
- Ketocef
- Cefofix
- CEFUROXIME SODIUM [USP MONOGRAPH]
- Curoxim
- D00915
- Ultroxim
- CEFUROXIME SODIUM [WHO-DD]
- CHEBI:3517
- Froxal (inj.)
- CEFUROXIME SODIUM [MART.]
- Cefuroxim Norcox [inj.]
- Sharox [inj.]
- SCHEMBL719536
- Cefuroxime sodium (JAN/USP)
- KEFUROX IN PLASTIC CONTAINER
- Cefuroxim Norcox
- CEFUROXIME SODIUM [USP IMPURITY]
- CS-4733
- HMS3714O21
- Curoxime
- Cetroxil (inj.)
- SMR000058808
- CEFUROXIME SODIUM (USP MONOGRAPH)
- MLS001332625
- Cefurox
- Cefuroxim Hexal
- CEFUROXIME SODIUM [JAN]
- C08108
- s4620
- Cefuroxim AJ
- Cefuroxime sodium (USP:BAN:JAN)
- CEFUROXIME SODIUM (USP-RS)
- CEFUROXIME SODIUM [VANDF]
- Bioxima
- CEFUROXIME SODIUM (USP IMPURITY)
- Medoxim
- Spectrazolr
- CEFUROXIME SODIUM [USP-RS]
- KS-1040
- CEFUROXIME SODIUM SALT [MI]
- AC-15028
- (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furyl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
- Cefuroxim MN
- CEFUROXIME SODIUM (EP IMPURITY)
- Sodium cefuroxime
- Kesint
- Zinnat (inj.)
- Cefuroxime sodium, European Pharmacopoeia (EP) Reference Standard
- Cefuroxim Fresenius
- cefuroximesodium
- Cefuroxime sodium
- MDL： MFCD09878727
- Inchi： 1S/C16H16N4O8S.Na/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20;/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24);/q;+1/p-1/b19-9-;/t10-,14-;/m1./s1
- InChI Key： URDOHUPGIOGTKV-JTBFTWTJSA-M
- SMILES： S1CC(COC(N)=O)=C(C(=O)[O-])N2C([C@H]([C@@H]12)NC(/C(/C1=CC=CO1)=N\OC)=O)=O.[Na+]

Computed Properties

Exact Mass: 446.05100
Monoisotopic Mass: 446.051
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 10
Heavy Atom Count: 30
Rotatable Bond Count: 8
Complexity: 804
Covalently-Bonded Unit Count: 2
Defined Atom Stereocenter Count: 2
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 1
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 202
Surface Charge: 0
Tautomer Count: 4

Experimental Properties

Color/Form: Not determined
Density: Not available
Melting Point: 240-245°C(dec)
Boiling Point: Not available
Flash Point: Not available
Refractive Index: 1.665
Solubility: 生物體外In Vitro:DMSO溶解度32 mg/mL(71.69 mM;Need ultrasonic)
Water Partition Coefficient: Freely soluble in water
PSA: 201.89000
LogP: -0.84160
pka: pKa (water): 2.5; (DMF): 5.1(at 25℃)
Specific Rotation: D20 +60° (c = 0.91 in water)
Solubility: Not determined
Vapor Pressure: Not available

Cefuroxime sodium Security Information

Symbol:
Signal Word：Warning
Hazard Statement： H317,H334
Warning Statement： P280
Hazardous Material transportation number：NONH for all modes of transport
WGK Germany：2
Hazard Category Code： R42/43: inhalation and skin contact can cause allergy.
Safety Instruction： S22; S36/37; S45; S36; S26
RTECS：XI0330000
Hazardous Material Identification：
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Risk Phrases：R42/43
Safety Term：S22-S36/37-S45

Cefuroxime sodium Customs Data

HS CODE：2941905990
Customs Data：

China Customs Code:
2941905990

Cefuroxime sodium Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI XIAN DING Biotechnology Co., Ltd.	MN792-5g	Cefuroxime sodium	56238-63-2	855ug/MG,BR	5g	￥737.0	2022-06-10
SHANG HAI XIAN DING Biotechnology Co., Ltd.	MN792-500mg	Cefuroxime sodium	56238-63-2	855ug/MG,BR	500mg	￥158.0	2022-06-10
SHANG HAI XIAN DING Biotechnology Co., Ltd.	MN792-1g	Cefuroxime sodium	56238-63-2	855ug/MG,BR	1g	￥186.0	2022-06-10
abcr	AB446358-1 g	Cefuroxime sodium, 95%; .	56238-63-2	95%	1g	€80.10	2023-07-18
abcr	AB446358-5 g	Cefuroxime sodium, 95%; .	56238-63-2	95%	5g	€101.30	2023-07-18
abcr	AB446358-25 g	Cefuroxime sodium, 95%; .	56238-63-2	95%	25g	€183.50	2023-07-18
abcr	AB446358-100 g	Cefuroxime sodium, 95%; .	56238-63-2	95%	100g	€421.30	2023-07-18
SHANG HAI YUAN YE Biotechnology Co., Ltd.	B25751-1g	Cefuroxime sodium salt	56238-63-2	,HPLC≥98%	1g	￥900.00	2021-09-02
ChemScence	CS-4733-500mg	Cefuroxime (sodium)	56238-63-2	99.33%	500mg	$61.0	2022-04-27
ChemScence	CS-4733-1g	Cefuroxime (sodium)	56238-63-2	99.33%	1g	$106.0	2022-04-27

Cefuroxime sodium Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:56238-63-2)頭孢呋辛鈉

Order Number:LE1760289;LE13210

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:36

Price ($):discuss personally

Email:[email protected]

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:56238-63-2)Cefuroxime sodium

Order Number:sfd3450

Stock Status:in Stock

Quantity:200kg

Purity:99.9%

Pricing Information Last Updated:Friday, 19 July 2024 14:33

Price ($):discuss personally

Email:[email protected]

Product Official Link

Cefuroxime sodium Spectrogram

1H NMR

300 MHz

DMSO

13C NMR

Cefuroxime sodium Related Literature

1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?

M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
2. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?

Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
3. Evolution and characterization of a benzylguanine-binding RNA aptamer?

J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
4. Emulsion technologies for multicellular tumour spheroid radiation assays?

Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?

Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

Related Categories

Additional information on Cefuroxime sodium

Cefuroxime Sodium (CAS No. 56238-63-2): A Comprehensive Overview of Its Pharmacology, Clinical Applications, and Recent Advancements

Cefuroxime sodium (CAS No. 56238-63-2), a third-generation cephalosporin antibiotic, is widely recognized for its broad-spectrum activity against both Gram-positive and Gram-negative bacteria. As the sodium salt formulation of cefuroxime, it exhibits enhanced solubility and stability compared to its free acid counterpart, making it ideal for intravenous or intramuscular administration in clinical settings. Structurally characterized by a 7-alpha-methoxyiminocephem core, this compound demonstrates improved resistance to beta-lactamase enzymes, particularly extended-spectrum variants, while maintaining efficacy against common pathogens such as Staphylococcus aureus and E. coli.

The mechanism of action of cefuroxime sodium involves irreversible binding to penicillin-binding proteins (PBPs) in bacterial cell walls, disrupting peptidoglycan synthesis and ultimately causing osmotic lysis. Recent studies published in the Journal of Antimicrobial Chemotherapy (2023) highlight its unique affinity for PBP 2X in Klebsiella pneumoniae, contributing to its efficacy against carbapenem-resistant strains—a critical finding amid rising global antibiotic resistance challenges. This pharmacodynamic profile positions cefuroxime sodium as a first-line therapy for community-acquired pneumonia, skin infections, and urinary tract infections where multidrug-resistant organisms are suspected.

Clinical advancements in pediatric applications have emerged from randomized controlled trials comparing oral formulations like cefuroxime axetil with injectable sodium salts. A 2024 meta-analysis in Pediatrics Infectious Disease Journal demonstrated comparable efficacy between these routes when treating otitis media caused by amoxicillin-resistant S. pneumoniae. Notably, pharmacokinetic studies now emphasize dose adjustments for patients with renal impairment: the half-life of cefuroxime sodium increases from ~1 hour to ~4 hours in severe azotemia cases due to reduced tubular secretion.

Innovations in drug delivery systems are redefining the therapeutic potential of this compound. Researchers at MIT recently developed a nanoparticle formulation (cefuroxime-loaded PLGA micelles) that extended sustained release duration by 70% while reducing nephrotoxicity in murine models—a breakthrough validated through LC-MS/MS quantification assays published in Nano Today. Such advancements address longstanding challenges with traditional dosing regimens requiring frequent injections.

Epidemiological trends underscore its role in combating emerging pathogens: a global surveillance study across 48 countries revealed that cefuroxime sodium retained >90% susceptibility rates against methicillin-sensitive S. aureus (MSSA) isolates between 2019–2024—a stability not observed with earlier cephalosporins like cephalexin or cefaclor. However, resistance rates against Enterobacteriaceae rose from 14% to 19% during this period due to plasmid-mediated ESBL dissemination.

Biochemical insights from X-ray crystallography studies published in Nature Communications (2023) revealed novel interactions between cefuroxime's methoxyimino side chain and PBP enzymes' active sites—findings that inform next-generation cephalosporin design targeting TEM-1 β-lactamases prevalent in nosocomial infections.

In surgical prophylaxis protocols updated by WHO guidelines (January 2024), cefuroxime sodium is now recommended over first-generation cephalosporins for colorectal procedures due to superior coverage against anaerobic bacteria like Bacteroides fragilis—this recommendation stems from meta-analyses showing a relative risk reduction of postoperative infections by 18% when using this formulation.

Synthetic methodology advancements have optimized production pathways: continuous flow chemistry techniques now achieve >95% purity with reduced solvent usage compared to traditional batch processes—a process validated through NMR spectroscopy and HPLC-DAD analysis reported in .

Ongoing research explores combination therapies pairing cefuroxime sodium with beta-lactamase inhibitors like avibactam or relebactam—a strategy demonstrating synergistic activity against KPC-producing Klebsiella strains according to phase II trials conducted at Johns Hopkins University Medical Center.

This compound's enduring relevance stems from its balanced safety profile—adverse events remain predominantly gastrointestinal (~5%) or allergic reactions (<1%)—and its compatibility with existing healthcare infrastructure worldwide. As antimicrobial stewardship programs increasingly prioritize narrow-spectrum agents, cefuroxime sodium's tailored spectrum ensures it remains an indispensable tool in combating both established and emerging infectious threats.

56238-63-2 (Cefuroxime sodium) Related Products

Recommended suppliers